Crohn's disease treatment - Controlled ileal release budesonide (9 mg / day)for ileum and / or right colon
Reply to this Note | Notes Linking Here | Crohn's disease Guidelines | 4K HDTV for $500 | Apple Macbook $1279 | Prior Note
Showing first five replies; total replies are 10. See all Replies
"Uncontrolled series have reported symptomatic improvement for upper GI CD with use of proton pump inhibitors" ...Read more | Crohns disease Guidelines
"parenteral methotrexate at a dose of 25 mg / week is e ective for steroid-dependent and steroid-refractory CD" Moderate to Severe Crohn's disease treatment ...Read more | Crohn's disease Guidelines
Choledocholithiasis - Risks and benefits of ERCP discussed with patient[] including bleeding, infection, perforation, pancreatitis, and death. Risk of pancreatitis stated as 15% for moderate pancreatitis and 1% for severe pancreatitis. Hand out describing procedure given to patient. Patient agreeable to proceed with ERCP.[] ...Read more | ERCP Beyond Hand out
Sucralfate enemas for radiation proctitis using sucralfate tablets and 4.5 ml of water ...Read more | Sucralfate tablet enemas article
Linzess dose for chronic idiopathic constipation is 145 mcg by mouth once a day ...Read more | Linzess Dosing Constipation
Crohn's disease treatment - Controlled ileal release budesonide (9 mg / day)for ileum and / or right colon
...Read more
"parenteral methotrexate at
a dose of 25 mg / week is e
ective for steroid-dependent and
steroid-refractory CD" Moderate to Severe Crohn's disease treatment
...Read more
"Dose-ranging studies have not been
performed to de ne an optimal dose or schedule of administration,
although most clinicians administer parenteral corticosteroids
equivalent to 40 – 60 mg of prednisone in divided doses" Severe Crohn's disease flare
...Read more
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab. 325 patients randomly assigned who were intolerant of infliximab or lost response. 21 % of adalimumab group had response versus 7% of placebo group.
...Read more
Adalimumab for Maintenance of Clinical Response and Remissionin Patients with Crohn's Disease; The CHARM Trial. Remission at week 56, 36% for every other week group.
...Read more
Vedolizumab in IBD. Crohn's disease, clinical response and remission were achieved in 54% (95% confidence interval (CI) 41-66%) and 22% (95% CI 13-35%) by week 6 and in 49% (95%CI 37-51%) and 32% (95%CI 23-42%) by week 14. Ulcerative colitis, clinical response and remission was achieved in 43% (CI 95% 37-49) and 25% (CI 95% 12-45) by week 6 and in 51% (95%CI 43-61%)and 30% (95%CI 24-36%) by week 14/22; at week 52, clinical response and remission.
...Read more
Humira for ulcerative colitis - randomized to receive HUMIRA 160 mg SC at Week 0, 80 mg SC at Week 2, and 40 SC mg at Weeks 4 and 6. Afterwards, Humira 40 mg SC every two weeks. Can consider Humira 40 mg SC weekly in some patients with Crohn's disease or ulcerative colitis.
...Read more
Crohn's disease treatment - Cimzia is a PEGylated TNF-blocker. Loading regimen is 400 mg on week 0, 400 mg on week 2, and 400 mg on week 4. Then use 400 mg every four weeks.
...Read more
Entyvio also known as Vedolizumab for Crohn's disease or ulcerative colitis: IV: 300 mg at 0, 2, and 6 weeks and then every 8 weeks thereafter.
...Read more
Stelera had a 65 percent remission rate at one year for Crohn’s disease.
...Read more